Mark G. Shaw

机构：Peter MacCallum Cancer Centre, Taranaki Base Hospital, Health New Zealand · ORCID：0000-0001-8324-8260

发表论文 53 篇 · 总被引 1982 次 · h-index 17

代表论文

• Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial (2019 · The Lancet Oncology · 被引 599)
• Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial (2018 · European Urology · 被引 325)
• Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial (2021 · European Urology · 被引 153)
• Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial (2017 · British Journal of Urology · 被引 121)
• Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial (2024 · The Lancet Oncology · 被引 120)
• Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II) (2021 · JAMA Oncology · 被引 92)